SAN

80.47

-1.02%↓

UCB

264.6

-0.53%↓

SHL.DE

37.34

-1.22%↓

ARGX

667.4

-0.06%↓

VIE

34.63

+0.41%↑

SAN

80.47

-1.02%↓

UCB

264.6

-0.53%↓

SHL.DE

37.34

-1.22%↓

ARGX

667.4

-0.06%↓

VIE

34.63

+0.41%↑

SAN

80.47

-1.02%↓

UCB

264.6

-0.53%↓

SHL.DE

37.34

-1.22%↓

ARGX

667.4

-0.06%↓

VIE

34.63

+0.41%↑

SAN

80.47

-1.02%↓

UCB

264.6

-0.53%↓

SHL.DE

37.34

-1.22%↓

ARGX

667.4

-0.06%↓

VIE

34.63

+0.41%↑

SAN

80.47

-1.02%↓

UCB

264.6

-0.53%↓

SHL.DE

37.34

-1.22%↓

ARGX

667.4

-0.06%↓

VIE

34.63

+0.41%↑

Kodu・Aktsiate loetelu・Nanobiotix

Search

N
Nanobiotix

Avatud

25.26 -4.68

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

25.34

Max

26.98

Põhinäitajad
By Trading Economics
Sissetulek	-5.4M
Müük	27M
Kasumimarginaal	-20.208
Töötajad	103
EBITDA	1.1M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+24.9% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	20. mai 2026

Turustatistika
By TradingEconomics
Turukapital	1.3B
Eelmine avamishind	29.94
Eelmine sulgemishind	25.26

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

2.975 / 3.015 Toetus ja vastupanu

Nanobiotix Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

8. apr 2026, 20:44 UTC

Tulu

Costco Reports 11% Growth in March Sales

8. apr 2026, 23:51 UTC

Market Talk

Global Equities Roundup: Market Talk

8. apr 2026, 23:51 UTC

Market Talk

Nikkei May Rise on Hopes for Talks to End Iran War -- Market Talk

8. apr 2026, 23:36 UTC

Market Talk

Uudisväärsed sündmused

Gold Edges Lower on Likely Technical Correction -- Market Talk

8. apr 2026, 22:56 UTC

Market Talk

Ramelius Resources May Downgrade Cost Guidance This Month -- Market Talk

8. apr 2026, 22:45 UTC

Market Talk

Constellation Brands Points to Continuing Challenges Among Hispanic Consumers -- Market Talk

8. apr 2026, 22:17 UTC

Market Talk

Applied Digital Says Its Holding Out for Quality Customers -- Market Talk

8. apr 2026, 21:52 UTC

Uudisväärsed sündmused

A Closer Look at Iran's 10 Demands -- and Which the U.S. Might Accept -- Update

8. apr 2026, 21:24 UTC

Tulu

FedEx Freight Aims for 12% Profit Growth. How That Compares to the Leader. -- Barrons.com

8. apr 2026, 21:01 UTC

Uudisväärsed sündmused

Oil Prices Tumble Despite Conflicting Reports About the Strait of Hormuz -- Barrons.com

8. apr 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

8. apr 2026, 20:43 UTC

Omandamised, ülevõtmised, äriostud

Oracle Is Expressing No Opinion and Is Neutral as to Whether Stockholders Should Tender Their Shrs in Response to TRC's Offer >ORCL

8. apr 2026, 20:43 UTC

Omandamised, ülevõtmised, äriostud

Oracle Does Not Endorse TRC's Mini-Tender Offer or the Offer Documentation >ORCL

8. apr 2026, 20:43 UTC

Omandamised, ülevõtmised, äriostud

Oracle: Offer Represents Less Than 0.04% of Outstanding Common Stk >ORCL

8. apr 2026, 20:42 UTC

Omandamised, ülevõtmised, äriostud

Oracle: TRC Offer Is to Purchase Up to 1M Shrs of Common Stk at $140.50/Shr in Cash >ORCL

8. apr 2026, 20:42 UTC

Omandamised, ülevõtmised, äriostud

Oracle Received Notice of Unsolicited Mini-Tender Offer by TRC Dated March 24 >ORCL

8. apr 2026, 20:42 UTC

Omandamised, ülevõtmised, äriostud

Oracle Responds to TRC Cap Mini-Tender Offer

8. apr 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8. apr 2026, 20:11 UTC

Omandamised, ülevõtmised, äriostud

Intel Corp.: Repurchased 49% Equity Interest in JV Related to Intel's Fab 34 in Ireland >INTC

8. apr 2026, 20:11 UTC

Omandamised, ülevõtmised, äriostud

Intel Corp.: $14.2B Repurchase Price Financed with Cash on Hand and a Bridge Loan of $6.5B >INTC

8. apr 2026, 20:11 UTC

Omandamised, ülevõtmised, äriostud

Intel Corp.: Repurchased JV Stake From Apollo-Managed Funds and Affiliates >INTC

8. apr 2026, 19:44 UTC

Tulu

These Companies Pay 5% Dividend Yields, and They're Hiking Them Too -- Barrons.com

8. apr 2026, 19:16 UTC

Market Talk

Hogs Follow Cutout Prices Lower -- Market Talk

8. apr 2026, 19:02 UTC

Market Talk

Global Energy Roundup: Market Talk

8. apr 2026, 19:02 UTC

Market Talk

Oil Futures Plunge as Cease-Fire Raises Hopes for Restored Supply -- Market Talk

8. apr 2026, 18:58 UTC

Market Talk

U.S. Natural Gas Futures Fall in Line With Slump in Oil -- Market Talk

8. apr 2026, 18:51 UTC

Market Talk

Global Equities Roundup: Market Talk

8. apr 2026, 18:51 UTC

Market Talk

Levi Strauss CEO Says Expanded Offerings, DTC Focus Are Working -- Market Talk

8. apr 2026, 18:14 UTC

Uudisväärsed sündmused

Fed Minutes Suggest a Lengthy Iran War Could Lead to Rate Hikes -- Barrons.com

8. apr 2026, 18:05 UTC

Uudisväärsed sündmused

Oil Prices Continue to Tumble After Cease-Fire Despite Slow Reopening of Strait of Hormuz -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Nanobiotix Prognoos

Hinnasiht

By TipRanks

24.9% tõus

12 kuu keskmine prognoos

Keskmine 32 EUR 24.9%

Kõrge 32 EUR

Madal 32 EUR

Põhineb 1 Wall Streeti analüütiku instrumendi Nanobiotix 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

1

Osta

0

Hoia

0

Müü

Põhineb 1 analüütiku instrumendi Nanobiotix aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

2.975 / 3.015Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

Muud aktsiad sektorist

SAN

Sanofi SA

80.47

UCB

UCB SA

264.6

SHL.DE

Siemens Healthineers AG

37.34

ARGX

Argenx SE

667.4

VIE

Veolia Environnement SA.

34.63

Live chat